1. Novel pharmacological approaches for antiarrhythmic therapy

   • Ursula Ravens

   EDITORIAL 15 January 2010 Pages: 187 - 193

2. Atrial Ca²⁺ signaling in atrial fibrillation as an antiarrhythmic drug target

   • Dobromir Dobrev

   REVIEW 26 September 2009 Pages: 195 - 206

   

3. Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance

   • Irene Savelieva
   • Antonios Kourliouros
   • John Camm

   REVIEW 25 November 2009 Pages: 207 - 219

   

4. Improving cardiac gap junction communication as a new antiarrhythmic mechanism: the action of antiarrhythmic peptides

   • Stefan Dhein
   • Anja Hagen
   • Friedrich-Wilhelm Mohr

   REVIEW 27 November 2009 Pages: 221 - 234

   

5. Cardiac adrenergic control and atrial fibrillation

   • Antony J. Workman

   REVIEW 04 December 2009 Pages: 235 - 249

   

6. Inhibition of I_K,ACh current may contribute to clinical efficacy of class I and class III antiarrhythmic drugs in patients with atrial fibrillation

   • Niels Voigt
   • Nadiia Rozmaritsa
   • Ursula Ravens

   ORIGINAL ARTICLE 17 September 2009 Pages: 251 - 259

   

7. The human cardiac K_2P3.1 (TASK-1) potassium leak channel is a molecular target for the class III antiarrhythmic drug amiodarone

   • Jakob Gierten
   • Eckhard Ficker
   • Dierk Thomas

   ORIGINAL ARTICLE 24 September 2009 Pages: 261 - 270

   

8. Synthesis and characterisation of NS13558: a new important tool for addressing KCa1.1 channel function ex vivo

   • Bo Hjorth Bentzen
   • Rune Wederkinck Andersen
   • Antonio Nardi

   ORIGINAL ARTICLE 02 October 2009 Pages: 271 - 283